Norwest Closes $4 Billion Fund, Its Largest in 65 Years

Norwest has closed its newest fund, Norwest 18, at $4 billion — the largest single fundraise in the firm's 65-year history — lifting total assets under management to $18 billion. The Palo Alto-headquartered firm disclosed the close this week and laid out where the money will go. That is a serious commitment of capital in a market where many peers are still raising smaller vehicles than their last ones.

The fund will back venture capital and growth equity investments across technology, healthcare and consumer sectors in the US, India and Israel. Those three geographies are not new territory for Norwest; the firm runs offices in Menlo Park and San Francisco, Mumbai and Tel Aviv. In plain terms, the $4 billion pool represents more than a fifth of everything Norwest now manages.

What does the firm's track record show?

Since launching its previous fund, Norwest 17, in April 2024, the firm has made more than 87 investments and supported over 30 portfolio companies through liquidity events — public listings and strategic acquisitions. That works out to an exit or listing roughly every few weeks across an 18-month-plus window, a pace few firms of any size can match.

Portfolio companies that went public during the period include India's Amagi Media Labs and Swiggy, alongside BillionToOne, MBX Biosciences and Omada Health. The acquisition list is longer:

• Avetta, bought by EQT
• AbsenceSoft, bought by Luminate Capital Partners
• Ouro Medicines, bought by Gilead Sciences
• Qualified, bought by Salesforce
• tvScientific, bought by Pinterest
• Veza, bought by ServiceNow

Norwest's existing portfolio also includes Babylist, Gong, Monogram Health, OfBusiness, VAST Data, Vuori and YipitData. The firm did not disclose which of its backers supplied the new $4 billion, nor the fees attached to the vehicle — details institutional investors usually scrutinize.

Where will the new money go?

Norwest says it is expanding its investment focus into five areas: next-generation financial infrastructure, physical and voice AI, agentic cybersecurity, technology-enabled industrial and aerospace businesses, and healthcare AI. Several of these themes already have funded names attached, which suggests the pivot predates the announcement.

In financial infrastructure, recent checks have gone to Beltic, Rain and Stablecore. In AI systems and agentic technologies, the firm backs Coval, Generalist AI and LlamaIndex. Cybersecurity positions include Above Security, ORION Security, Red Access and Zenity. Industrial and aerospace bets span East Range Group, Padmini VNA, JJG Aerospace and Raghu Vamsi Aerospace Group.

Healthcare is the fifth pillar. Norwest has invested in Infinx, Matchpoint Therapeutics, Rezo Therapeutics, Tokaido Health and Vitalize Care — companies applying technology and AI to drug discovery, clinical workflows and healthcare delivery. Whether these newer bets can produce outcomes on the scale of the Swiggy and Omada Health listings remains the open question.

Is Norwest offering more than capital?

Beyond funding, the firm says it provides strategic advisory and operational support. It has doubled its Senior Advisor Network, added Operating Executives and launched two programs: the Norwest Operator Collective and Norwest Kinetic. The firm offered no figures on how those initiatives have affected portfolio performance — a notable omission, given that support services are often marketed harder than they are measured.

Founded in 1961, Norwest has invested in more than 750 companies over six decades and currently partners with over 275 businesses across its venture and growth portfolios. That scale gives it roughly one active portfolio company for every $65 million of assets under management.

The $4 billion close signals that limited partners still reward a firm with a documented exit record — 30-plus liquidity events in under two years — even as they grow warier of AI-driven valuations elsewhere. The test now is whether Norwest's five new theses, from agentic cybersecurity to healthcare AI, can convert fresh capital into the same caliber of listings and acquisitions.